Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The Accelerating Medicines Partnership in Heart Failure is designed to deliver tools and knowledge that enable the development of new approaches to treat heart failure with preserved ejection fraction, which is considered the largest unmet need in cardiovascular medicine.
Pearl Huang, incoming CEO of Dunad Therapeutics, is betting that covalent drugs can push the boundaries of the small-molecule modality to supercharge targeted protein degradation.